Chondroitin rivals Celecoxib for osteoarthritis symptoms

“There is now more than 20 years of clinical and empirical evidence supporting the benefits of supplement use, prompting the need to review current clinical orthopedic guidelines on the use of high-quality supplements and their ability to impact patient outcomes.” Dr. Brian Cornblatt, Medical Director of Nutramax Laboratories

Croatia Water Polo Gold 2012 London Olympics

Laird Harrison, Medscape Multispecialty November 10, 2015

SAN FRANCISCO — Chondroitin, typically considered more a nutritional supplement than a treatment option, can slow the long-term progression of knee osteoarthritis while matching the symptom relief of celecoxib, an eyebrow-raising study presented here at the American College of Rheumatology 2015 Annual Meeting has found.

“This is quite significant,” said presenter Jean-Pierre Pelletier, MD, from the division of rheumatology at the University of Montréal.

Researchers have long debated the effectiveness of chondroitin, which is derived from sources such as beef and shark cartilage, for the treatment osteoarthritis. In the United States, it is sold as a nutritional supplement; in Europe, it is sometimes prescribed as a pharmaceutical.

To assess the effectiveness of chondroitin, Dr Pelletier and his team recruited 194 patients with primary knee osteoarthritis.

All had radiographic evidence of Kellgren–Lawrence grade 2 or 3, signs of synovitis, and a minimum joint space width of at least 2 mm in the medial femorotibial compartment evident on standing knee x-ray. And all had knee pain for the previous month and a visual analogue scale (VAS) score of pain while walking of at least 40 mm.

Half the patients were randomized to receive pharmaceutical-grade chondroitin sulphate (Condrosan, Bioibérica) 1200 mg daily. The other half, who served as the control group, were randomized to receive celecoxib (Celebrex, Pfizer) 200 mg daily.

Patients at risk for cardiovascular or gastrointestinal events were excluded from the analysis because of the fear that celecoxib would trigger such an event.

All patients were allowed acetaminophen, up to 3 g per day, as a rescue medication.

Changes in Cartilage

The researchers chose celecoxib rather than a placebo because it has been shown to relieve symptoms but does not have any effect on the structure of the knee in osteoarthritis. It was important to provide some pain relief so the patients in the control group would stay in the study, Dr Pelletier explained.

The two groups were similar in sex, age, pain, and body mass index. They were also similar in pain, stiffness, and physical function, measured on the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index and the VAS. Average age was 61 years, and average BMI was 31 kg/m².

Over the 2-year study period, the number of patients who dropped out because of lack of efficacy, adverse events, loss to follow-up, protocol violation, and miscellaneous other problems was similar in the two groups. In the final analysis, there were 58 in the chondroitin group and 63 patients in the control group.

The researchers used MRI to measure changes in the cartilage and other structural elements of the knees. After 12 months, a difference in cartilage loss in the medial compartment emerged between the two groups, which persisted out to 24 months.

“Chondroitin sulfate was significantly better at reducing cartilage loss, and both treatments were found to be equally effective at reducing symptoms over time,” Dr Pelletier reported.

Outcome Chondroitin
Group
Celecoxib Group P Value
Global knee cartilage loss, % –5.76 –6.51 .054
Medial compartment cartilage loss, % –6.69 –8.14 .013
Synovial fluid volume change, mL –3.86 –2.13 .494
WOMAC pain change, % –46.4 –53.0 .415
VAS pain change, % –49.2 –55.4 .439
Table. Two-Year Outcomes

Although there was no overall difference between the two groups in the thickness of the synovial membrane, there was a marked reduction in synovial thickness in a subgroup of the chondroitin patients, said Dr Pelletier.

But chondroitin sold as a nutritional supplement might not provide the same benefits as the pharmaceutical-grade chondroitin used in the study, he cautioned.

Dr Pelletier said he is already using chondroitin in osteoarthritis. He typically starts with a “soft” drug, such as acetaminophen, and if that doesn’t work, he progresses to chondroitin and glucosamine, he told Medscape Medical News.

If these treatments don’t produce satisfactory results, he tries short-term treatment with nonsteroidal anti-inflammatory drugs to control spikes in pain.

However, it might be too early to recommend the use of chondroitin, said session moderator Kelli Allen, PhD, from the University of North Carolina at Chapel Hill.

This study has not yet passed the scrutiny of a peer-reviewed journal, and must be balanced against negative outcomes in other chondroitin trials, she said. “The evidence is equivocal.”

Source Medscape Multispecialty via PR Newswire

  References

Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study, Pelletier JP, Raynauld JP, Beaulieu AD, Bessette L, Morin F, de Brum-Fernandes AJ, Delorme P, Dorais M, Paiement P, Abram F, Martel-Pelletier J. Arthritis Res Ther. 2016 Nov 3;18(1):256. doi: 10.1186/s13075-016-1149-0. Full text

In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients, Jean-Pierre Pelletier, Jean Pierre Raynauld, André Beaulieu, Louis Bessette, Frédéric Morin, Artur J Fernandes, François Abram, Marc Dorais, Johanne Martel-Pelletier. American College of Rheumatology (ACR) 2015 Annual Meeting: Abstract 950. Presented November 8, 2015.

  Further reading

Osteoarthritis, Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, Goldring SR, Jones G, Teichtahl AJ, Pelletier JP. Nat Rev Dis Primers. 2016 Oct 13;2:16072. doi: 10.1038/nrdp.2016.72.

Investigational drugs for the treatment of osteoarthritis, an update on recent developments, Zhu Z, Li J, Ruan G, Wang G, Huang C, Ding C. Expert Opin Investig Drugs. 2018 Nov;27(11):881-900. doi: 10.1080/13543784.2018.1539075. Epub 2018 Oct 24.

Chondroitin and Glucosamine in the Management of Osteoarthritis: An Update,  Henrotin Y, Lambert C. Curr Rheumatol Rep. 2013 Oct;15(10):361. doi: 10.1007/s11926-013-0361-z.

Epidemiology of osteoarthritis, Zhang Y, Jordan JM. Clin Geriatr Med. 2010 Aug;26(3):355-69. doi: 10.1016/j.cger.2010.03.001. Erratum in: Clin Geriatr Med. 2013 May;29(2):ix. Full text

Epidemiology of osteoarthritis and associated comorbidities, Suri P, Morgenroth DC, Hunter DJ. PM R. 2012 May;4(5 Suppl):S10-9. doi: 10.1016/j.pmrj.2012.01.007.

Also see
New Clinical Evidence Finds Chondroitin Sulfate Superior to Celecoxib at Reducing Cartilage Loss in Knee Osteoarthritis PR Newswire
Nutramax Laboratories Release; New Clinical Evidence Finds Chondroitin Sulfate Superior To Celecoxib At Reducing Cartilage Loss In Knee Osteoarthritis Biospace

Mobility Menu
   403-240-9100

follow us in feedly
Call 403-240-9100